Our Team

Nadja Mrosek, MD, PhD

Chief Executive Officer

Co-founder of Glycemicon. Nadja is a medical doctor by training who studied at the University of Heidelberg. The research for her doctoral thesis was done at the ETH Zürich in the Institute of Molecular Systems Biology in the field of obesity and applied diabetes research. After working clinically in Germany, Australia and Switzerland, she returned to ETH and obtained her PhD at the Institute of Food, Nutrition and Health. In addition to her medical expertise and her experience in the lab, she completed a training in clinical trial management.

Peter Harboe-Schmidt, MSc, MBA

Head of Finance, Communication and Marketing

Co-founder of Glycemicon. Peter has a wealth of start-up and industry experience in the biotechnology sector. He has co-founded SpiroChem AG and Xigen Pharma SA. As Head of Business Development at Modex Therapeutics, he played a key role in the company`s IPO on the Swiss Stock exchange. Prior to this, he was Head of Market Research and Business Planning at Amgen Europe. In addition, he worked in various managerial positions, e.g. manufacturing, sales and Business Development at DuPont de Nemours. As a CTI Startup coach, he has advised and guided the founders and CEOs of over 30 Swiss life science companies.

Emilie Frugier, PhD

Head of Intellectual Property Management

Emilie studied chemistry at McGill University (Canada) and the Ecole Nationale Superieure de Chimie de Paris (France). Her doctoral thesis from Department of Biochemistry of the University of Zurich was in the field of computational structural biology. She also holds a Masters of Advance Studies in Intellectual Property from the ETH Zurich, and has several years of industrial/biotech experience as an intellectual property officer. Emilie combines her background in therapeutics development with her knowledge of patents to secure the right for Glycemicon to advance their innovative products.

Thomas Fessard, PhD

Head of Manufacturing

Thomas Fessard obtained his PhD degree from the University of Nottingham, UK. Thomas is the co-founder of SpiroChem AG, a world leading innovator and manufacturer of novel building chemical blocks for use in drug discovery. Thomas has over 10 years of industry experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process route.

Robert Schier, PhD, MBA

Robert Schier received academic degrees in pharmacy, applied microbiology and cell biology, as well as in business administration. He is co-author of several patents and scientific publications, and received the Keystone Award for Excellence in Research. Robert held several R&D and business positions in biotech companies in the Munich area before becoming a partner in the venture capital firms Inventages (2002-2011) and then Seventure Partners (2011-2016). In both these firms he invested in life science companies in Europe and the US as a lead investor, and served as a director on the boards of several portfolio companies. Robert now also acts as a start-up coach for the Swiss Commission for Technology and Innovation. In 2016, he joined Glycemicon as a board member and currently serves as Chairman.

Peter Harboe-Schmidt, MSc, MBA

Co-founder of Glycemicon. Peter has a wealth of start-up and industry experience in the biotechnology sector. He has co-founded SpiroChem AG and Xigen Pharma SA. As Head of Business Development at Modex Therapeutics, he was playing a key role for the company`s IPO on the Swiss Stock exchange. Prior to this, he was Head of Market Research and Business Planning at Amgen Europe. In addition he worked in various managerial positions, e.g. manufacturing, sales and Business Development at DuPont de Nemours. As a CTI Startup coach, he has advised and guided the founders and CEOs of over 30 Swiss life science companies.

Danilo Casadei Massari, BSc

Danilo holds a Bachelor of Science and trained in Epidemiology. He has extensive experience as a senior pharmaceutical executive and as an entrepreneur. Among others, he has co-founded and is operationally active in Prismic Pharmaceuticals and Primary Medicines. Prior to this, in 2011, he successfully founded, built and sold a medical foods company, CM&D Pharma, to Nestle Health Science. Earlier in his career he was CEO of Fidia Pharmaceuticals, USA, and Director of International Corporate Development with Fidia Farmaceutici SpA and Madaus. In parallel to his current operational activities, Danilo is a member of the Investment Committee at Seventure Partners in Paris. He serves as a director with TargEDys, Cambrooke Therapeutics, Theraloop, Documedica and Difass International.

Erhard Lee, MBA

Erhard holds a master’s degree in business economics and administration. He is a certified analyst and wealth manager. Erhard started his career at BZ Bank in 1992 as an analyst and head of trading. In 1995, he joined Bank Leu AG, where he was a portfolio manager for a Swiss equity fund before joining Actieninvest in 1996 as an analyst, wealth manager and CEO. Erhard joined Schaller Management and Consulting in 2001, where he spent two years as CEO, partner and wealth manager. At the same time, he founded his own investment firm, AMG Analysen und Anlagen, which today manages assets of over 1 billion with offices in Zurich and Zug, Switzerland.

Antonino Santoro, PhD

Antonino has more than 40 years experience in the food and pharmaceutical business. He started his career in the Pharmacological Institute “Mario Negri” in Milan and was later responsible for Regulatory Affairs and Business Development in Rottapharm/Madaus, playing a key role in the company´s transformation into a truly multinational organization. Presently, he is also serving on the Board of Directors of Sifi S.p.A, an Italian ophtalmic pharma company and of several other small companies active in the food supplements area. Antonino is the Vice-President of Federsalus, the Italian Association of Food Supplements Manufacturers and Distributors. Since 2013, he is a Member of the Board of the European Federation of Health Product Manufacturer Associations (EHPM).

Prof. Christian Wolfrum, PhD

Co-founder of Glycemicon. Christian studied chemistry at the University of Münster, Germany and the Texas A&M University, College Station, USA. His PhD research together with Prof. Fritz Spener at the Department of Biochemistry, University Münster focused on the intracellular transport of lipids and their effect on transcriptional control of metabolism. He carried out his postdoctoral research in the group of Prof. Markus Stoffel at the Rockefeller University, NYC, USA where he focused on signaling cascades that regulate lipid metabolism in obesity and type 2 diabetes. In 2008 Christian was appointed assistant professor for obesity research at the Swiss Federal Institute of Technology (ETH Zürich). Since 2010 he is associate professor for Translational Nutrition Biology at the Department of Health Science and Technology. His group works on adipose tissue development and how this effects whole body energy metabolism and homeostasis. He is the recipient of many awards and prizes.

Prof. Erick M. Carreira, PhD

Co-founder of Glycemicon. Erick holds a B.S. from the University of Illinois at Urbana Campaign and obtained his Ph.D. degree in Chemistry from Harvard University working with Prof. Dr. David A. Evans. He carried out his postdoctoral work at the California Institute of Technology with Peter Dervan and joined the Caltech faculty as an assistant professor of chemistry in 1992 advancing to full professor in 1997. Since 1998 he leads the laboratory of organic chemistry at the Swiss Federal Institute of Technology (ETH Zürich) as full professor. His research focuses on the synthesis of biologically active natural products, as well as medicinal and bioorganic chemistry. He is the recipient of numerous prizes and awards.

Christof Jänicke, MD, MBA

Chief Medical and Regulatory Officer

Christof received an MBA in Business Administration as well as Marketing and Advertising Management prior to studying medicine at the Free University (Freie Universität) in Berlin. He worked as Manager/Director of the OTC or NTP departments for several renowned companies including Ciba Geigy, Sterling-Winthrop and Fresenius before becoming the CEO of Marketing and Sales of Lichtwer Pharma. He went on to found Background Consultancy in 1992 and PhytoPharm Consulting in 1996 which ultimately led to the incorporation of analyze & realize ag (a&r) in 2001. Since 2013, he played a key role for setting up Glycemicon´s regulatory and clinical strategy.

Christof passed away peacefully in early 2017 after a short and intense last battle he could not win. He will be remembered as a great family man, a strong character, a loyal friend, a passionate entrepreneur and a highly esteemed team member.